Published in the Journal of the American Veterinary Medical Association (JAVMA), the latest in a series of complementary studies from PetDx reinforces scientific foundation of next-generation sequencing-based “liquid biopsy” testing for early cancer detection in dogs and raises benchmark for transparency in postmarketing clinical experience reporting in veterinary diagnostics.
Next-Generation Sequencing-Based ‘Liquid Biopsy’ at Wellness Visits Can Increase Early Cancer Detection in Dogs, PetDx Study Shows
Published in the Journal of Veterinary Internal Medicine, the study of over 350 dogs found that detection of cancer at wellness visits was rare and suggested that blood-based “liquid biopsy” testing with OncoK9 could increase preclinical detection at these visits.
Dogs Should Be Screened for Cancer Beginning at Age 7, as Early as Age 4 for Certain Breeds, PetDx Study Shows
Published in PLOS ONE, the study of over 3,000 dogs provides evidence-based recommendations to start screening dogs for cancer based on the median age at diagnosis by breed or weight.
PetDx analyses demonstrate the potential of OncoK9 for detection of residual disease following excisional surgery and detection of cancer recurrence following therapy.
OncoK9, the Pioneering Blood-Based Early Cancer Detection Test for Dogs, Now Available in Asia Through Asia Veterinary Diagnostics
In the first expansion of access beyond North America, the OncoK9® test from PetDx® is now available in Hong Kong, Singapore, Malaysia, South Korea, and Cambodia at veterinary clinics served by Asia Veterinary Diagnostics.
Antech Diagnostics and PetDx Expand Access to OncoK9, the Multi-Cancer Early Detection Test for Dogs
The strategic relationship announced today makes OncoK9 immediately available to all Antech customers in the United States and Canada
PetDx® – The Liquid Biopsy Company for Pets™ is participating in the Stifel 2022 Jaws & Paws Conference taking place in New York City on Wednesday, June 1, 2022. PetDx Founder and CEO Daniel S. […]
PetDx Announces Publication of Landmark Clinical Validation Study for OncoK9, Its Pioneering Multi-Cancer Early Detection Test for Dogs Using Next-Generation Sequencing
Published in PLOS ONE, the CANcer Detection in Dogs (CANDiD) study–the largest clinical validation study in veterinary cancer diagnostics–sets a new benchmark for veterinary medicine
Veterinarians Using OncoK9 Liquid Biopsy Test in Complex Clinical Cases Can Consult with Specialists Through the Fidu Telemedicine Platform
Access to Internal Medicine and Oncology Consultations Will Support Veterinarians Prescribing First-in-Class Multi-Cancer Early Detection (MCED) Test from PetDx®
The collaborative effort makes OncoK9 available immediately to veterinary customers served by IDEXX Reference Laboratories
PetDx Raises $62 Million in Series B Financing to Scale Adoption of its Canine Multi-Cancer Early Detection Blood Test, OncoK9
OncoK9® is a first-in-class multi-cancer early detection (MCED) test that employs next-generation sequencing (NGS) to detect many types of cancer in dogs with a simple blood draw.
OncoK9 Initially Available at Select Petco Full-Service Veterinary Hospitals Beginning in May